These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7097505)

  • 21. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition and oxidative metabolism of phenylbutazone in man.
    Aarbakke J; Bakke OM; Milde EJ; Davies DS
    Eur J Clin Pharmacol; 1977; 11(5):359-66. PubMed ID: 880975
    [No Abstract]   [Full Text] [Related]  

  • 23. Absorption of phenylbutazone from a paste formulation administered orally to the horse.
    Lees P; Higgins AJ; Mawhinney IC; Reid DS
    Res Vet Sci; 1986 Sep; 41(2):200-6. PubMed ID: 3775111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of tobacco on the serum levels and pharmacokinetics of phenylbutazone and oxyphenbutazone].
    Queneau P; Ollagnier M; Decousus H; Perpoint B; Brazier JL; Faucon L
    Rev Rhum Mal Osteoartic; 1983 Apr; 50(4):293-7. PubMed ID: 6879097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of pirazolac--a new anti-inflammatory drug--in human volunteers. I. Absorption, disposition, biotransformation and excretion.
    Täuber U; Weiss C; Krause W; Acksteiner B; Matthes H
    Eur J Drug Metab Pharmacokinet; 1985; 10(1):41-53. PubMed ID: 4029220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetic profile of pyrazinobutazone in man.
    von Bruchhausen V; Lohmann H; O'sváth J
    Arzneimittelforschung; 1978; 28(12):2337-43. PubMed ID: 582952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
    Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
    Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenylbutazone kinetics and metabolite concentrations in the horse after five days of administration.
    Soma LR; Gallis DE; Davis WL; Cochran TA; Woodward CB
    Am J Vet Res; 1983 Nov; 44(11):2104-9. PubMed ID: 6650958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
    Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
    Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenylbutazone and oxyphenbutazone distribution into tissue fluids in the horse.
    Lees P; Taylor JB; Higgins AJ; Sharma SC
    J Vet Pharmacol Ther; 1986 Jun; 9(2):204-12. PubMed ID: 3723663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism, excretion and pharmacokinetics of [
    Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
    Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of phenylbutazone in camels.
    Wasfi IA; Abdel Hadi AH; Zorob O; Osman M al-G ; Boni NS
    Am J Vet Res; 1997 Jun; 58(6):636-40. PubMed ID: 9185972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats.
    Cheng Z; Welsh E; Nolan A; McKellar QA
    Vet Rec; 1997 Jan; 140(2):40-3. PubMed ID: 9123796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sensitivity of human bone marrow granulocyte/monocyte precursor cells to phenylbutazone, oxyphenbutazone and gamma-hydroxyphenylbutazone in vitro, with observations on the bone marrow colony formation in phenylbutazone-induced granulocytopoenia.
    Smith CS; Chinn S; Watts RW
    Biochem Pharmacol; 1977 May; 26(9):847-52. PubMed ID: 861050
    [No Abstract]   [Full Text] [Related]  

  • 35. The absorption, metabolism and excretion of (14C)-AR-L 115 BS in the baboon.
    Cameron BD; Draffan GH; Dunsire JP; Zimmer A
    Arzneimittelforschung; 1981; 31(1a):217-20. PubMed ID: 7195225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.
    Pond SM; Birkett DJ; Wade DN
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):573-9. PubMed ID: 913025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uricosuric activity of suxibuzone, a new phenylbutazone derivative.
    Erill S; Laporte J
    Arch Farmacol Toxicol; 1975 Mar; 1(1):43-6. PubMed ID: 1231648
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses.
    Andrews FM; Reinemeyer CR; Longhofer SL
    Vet Ther; 2009; 10(3):113-20. PubMed ID: 20037965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of bumadizone-, phenylbutazone- and oxyphenbutazone-plasma levels after a single oral dose of phenylbutazone and of bumadizone, respectively (author's transl)].
    Spahn H; Mutschler E; Geissler HE; Faust-Tinnefeldt G
    Arzneimittelforschung; 1981; 31(3):499-503. PubMed ID: 6894380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The absorption, excretion, and biotransformation of 3,4,4'-trichlorocarbanilide in humans.
    Hiles RA; Birch CG
    Drug Metab Dispos; 1978; 6(2):177-83. PubMed ID: 26534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.